VJET.OB es geht weiter hoch!!! - 500 Beiträge pro Seite
eröffnet am 29.06.05 16:14:55 von
neuester Beitrag 11.07.05 17:54:21 von
neuester Beitrag 11.07.05 17:54:21 von
Beiträge: 18
ID: 990.208
ID: 990.208
Aufrufe heute: 0
Gesamt: 633
Gesamt: 633
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
heute 04:10 | 710 | |
vor 1 Stunde | 557 | |
gestern 22:29 | 424 | |
vor 25 Minuten | 422 | |
heute 00:54 | 406 | |
gestern 23:08 | 379 | |
gestern 21:39 | 379 | |
gestern 21:53 | 372 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.500,48 | -0,12 | 117 | |||
2. | 2. | 0,1800 | -83,67 | 74 | |||
3. | 4. | 2.231,78 | +1,79 | 54 | |||
4. | 3. | 20,910 | -5,47 | 49 | |||
5. | 5. | 175,79 | -2,25 | 37 | |||
6. | 17. | 2,6200 | -14,94 | 36 | |||
7. | 6. | 4,9230 | -0,47 | 35 | |||
8. | 9. | 0,2105 | -3,22 | 34 |
Gestern schon 180%
WKN 165219
Irgendwas mit Augen OP Geräte
Grüße
WKN 165219
Irgendwas mit Augen OP Geräte
Grüße
Shares gerade mal 28Mill.
Kurs gerade bei 0,06
VisiJet Inc., is rebranding the company and will now be doing business as Advanced Refractive Technologies, Inc. (ART). VisiJet is unveiling the Advanced Refractive Technologies name to the ophthalmic community through a series of advertisements in leading ophthalmic trade journals.
As reported by Cataract & Refractive Surgery Today, Anamed, Inc., which has been rebranded as Intralens Vision, Inc. by the firm`s new president and CEO, Randy Alexander, is working toward FDA approval of its intracorneal lens, which is currently undergoing clinical trials in the US for hyperopic corrections of up to +6.00D. Intralens Vision intends to develop, manufacture, and market intracorneal lenses composed of its unique microporous hydrogel material.
VisiJet, Inc., dba Advanced Refractive Technologies (ART), has received approval from the Health Ministry of Japan to market and sell its EpiLift System, a medical device that enables a potentially safer form of laser eye surgery called Epi LASIK. The company also announced that it had signed agreements with three different distributors to market and sell the EpiLift System in Japan, Thailand, Indonesia, Singapore, Malaysia and Brunei.
Arbeiten mit einer deutschen Firma zusammen
Gebauer Med.Technik
VisiJet Inc. (OTC BB: VJET), dba Advanced Refractive Technologies (ART), a developer and marketer of innovative technologies for the ophthalmic surgical market, received licensed approval from Health Canada, the federal department responsible for helping the people of Canada maintain and improve their health, to market and sell the EpiLift System in Canada.
The EpiLift System is already being sold in over 30 countries including the United States, Japan and in most countries in Europe. The system is the cornerstone of Epi-LASIK, a new, safer method of the popular LASIK corrective vision surgery.
"Canada is a difficult market to enter due to its stringent safety requirements, which are very similar to those in the United States. Gaining this approval from Health Canada is further testimony to the efficacy and safety of the EpiLift device. It is also an extremely important market that will enable us to expand our North American reach." said Randy Bailey, CEO.
About the EpiLift System
When the EpiLift System is used, the epithelium - the top layer of the eye - is cleanly separated, at a natural division point in the eye, from the Bowman`s layer membrane in an intact sheet of viable tissue. The tissue is then lifted away from the cornea so that a laser can be applied to reshape it. This entire process, Epi-LASIK, produces virtually instant visual results similar to LASIK but with the stable long-term visual outcomes of PRK.
LASIK surgery, currently a standard corrective vision surgical process, requires making a flap in the top layer of the eye before the laser is applied. This flap, once created, never fully heals, which can lead to complications and possible vision impairment in the future. Because it does not involve cutting the cornea or creating a permanent flap, the EpiLift System allows the eye to regrow the connections with the epithelium, resulting in a safer procedure with a significantly lower risk of complications
http://www.expertsinternational.com/arons/
Viel Glück
Kurs gerade bei 0,06
VisiJet Inc., is rebranding the company and will now be doing business as Advanced Refractive Technologies, Inc. (ART). VisiJet is unveiling the Advanced Refractive Technologies name to the ophthalmic community through a series of advertisements in leading ophthalmic trade journals.
As reported by Cataract & Refractive Surgery Today, Anamed, Inc., which has been rebranded as Intralens Vision, Inc. by the firm`s new president and CEO, Randy Alexander, is working toward FDA approval of its intracorneal lens, which is currently undergoing clinical trials in the US for hyperopic corrections of up to +6.00D. Intralens Vision intends to develop, manufacture, and market intracorneal lenses composed of its unique microporous hydrogel material.
VisiJet, Inc., dba Advanced Refractive Technologies (ART), has received approval from the Health Ministry of Japan to market and sell its EpiLift System, a medical device that enables a potentially safer form of laser eye surgery called Epi LASIK. The company also announced that it had signed agreements with three different distributors to market and sell the EpiLift System in Japan, Thailand, Indonesia, Singapore, Malaysia and Brunei.
Arbeiten mit einer deutschen Firma zusammen
Gebauer Med.Technik
VisiJet Inc. (OTC BB: VJET), dba Advanced Refractive Technologies (ART), a developer and marketer of innovative technologies for the ophthalmic surgical market, received licensed approval from Health Canada, the federal department responsible for helping the people of Canada maintain and improve their health, to market and sell the EpiLift System in Canada.
The EpiLift System is already being sold in over 30 countries including the United States, Japan and in most countries in Europe. The system is the cornerstone of Epi-LASIK, a new, safer method of the popular LASIK corrective vision surgery.
"Canada is a difficult market to enter due to its stringent safety requirements, which are very similar to those in the United States. Gaining this approval from Health Canada is further testimony to the efficacy and safety of the EpiLift device. It is also an extremely important market that will enable us to expand our North American reach." said Randy Bailey, CEO.
About the EpiLift System
When the EpiLift System is used, the epithelium - the top layer of the eye - is cleanly separated, at a natural division point in the eye, from the Bowman`s layer membrane in an intact sheet of viable tissue. The tissue is then lifted away from the cornea so that a laser can be applied to reshape it. This entire process, Epi-LASIK, produces virtually instant visual results similar to LASIK but with the stable long-term visual outcomes of PRK.
LASIK surgery, currently a standard corrective vision surgical process, requires making a flap in the top layer of the eye before the laser is applied. This flap, once created, never fully heals, which can lead to complications and possible vision impairment in the future. Because it does not involve cutting the cornea or creating a permanent flap, the EpiLift System allows the eye to regrow the connections with the epithelium, resulting in a safer procedure with a significantly lower risk of complications
http://www.expertsinternational.com/arons/
Viel Glück
Vom Mai
VisiJet, Inc. closed on a financing of $4.9 million. VisiJet plans to use the funds to support marketing and sales of its lead product, the EpiLift System, and to improve its short-term debt structure. The EpiLift System is a new, safer refractive surgery technique that enables ophthalmologists to perform EpiLASIK surgery with fewer postoperative complications than existing methods. Six firms participated in the financing, including Renaissance Capital, Corsair Capital, Roaring Fork Capital Management, Alpha Capital AG, Little Gem Life Sciences, and Liberty View Capital.
The February issue of Ophthalmic Market Perspectives reported on Q4 2004 refractive procedures. According to editor David Harmon, growth in refractive surgery, which had been growing at more than 19% for the first three quarters, slowed during Q4. He remarked that the slowdown was primarily due to weakening consumer confidence during October and November, that delayed decisions for potential LASIK patients. He estimated that the total U.S. laser refractive procedures for the fourth quarter were 276,000, up 7.3% when compared with the 257,200 procedures performed during Q4 2003. When non-laser procedures, including conductive keratoplasty, refractive lens exchange, and phakic IOLs are included, U.S. refractive procedures increased 11.5%. In addition, an estimated 6200 patients traveled to Canada and Mexico bringing total Q4 procedures to 298,200, an overall increase of 11.1%. Overall, Q4 2004 procedures declined 5.1% compared to a seasonally stronger Q3 2004.
VisiJet, Inc. closed on a financing of $4.9 million. VisiJet plans to use the funds to support marketing and sales of its lead product, the EpiLift System, and to improve its short-term debt structure. The EpiLift System is a new, safer refractive surgery technique that enables ophthalmologists to perform EpiLASIK surgery with fewer postoperative complications than existing methods. Six firms participated in the financing, including Renaissance Capital, Corsair Capital, Roaring Fork Capital Management, Alpha Capital AG, Little Gem Life Sciences, and Liberty View Capital.
The February issue of Ophthalmic Market Perspectives reported on Q4 2004 refractive procedures. According to editor David Harmon, growth in refractive surgery, which had been growing at more than 19% for the first three quarters, slowed during Q4. He remarked that the slowdown was primarily due to weakening consumer confidence during October and November, that delayed decisions for potential LASIK patients. He estimated that the total U.S. laser refractive procedures for the fourth quarter were 276,000, up 7.3% when compared with the 257,200 procedures performed during Q4 2003. When non-laser procedures, including conductive keratoplasty, refractive lens exchange, and phakic IOLs are included, U.S. refractive procedures increased 11.5%. In addition, an estimated 6200 patients traveled to Canada and Mexico bringing total Q4 procedures to 298,200, an overall increase of 11.1%. Overall, Q4 2004 procedures declined 5.1% compared to a seasonally stronger Q3 2004.
54 Wochen hoch bei 0,84
SAN CLEMENTE, Calif. & PLANT CITY, Fla.--(BUSINESS WIRE)--May 31, 2005--VisiJet, Inc. (OTCBB:VJET - News) a medical device company, and UTEK Corporation (AMEX:UTK - News; LSE-AIM:UTKA) an innovative technology transfer company, announced today the signing of a strategic alliance agreement.
ADVERTISEMENT
Randy Bailey, President and Chief Executive Officer of VisiJet, Inc., said, "We are enthusiastic about this strategic alliance with UTEK Corporation which will enable us to identify ophthalmic technologies for acquisition."
"UTEK looks forward to working with VisiJet, Inc. to identify and potentially transfer proprietary technologies that will be synergistic with their core business," said Clifford M. Gross, Ph.D., Chairman and Chief Executive Officer of UTEK.
Through its strategic alliance agreements, UTEK assists companies in enhancing their new product pipeline with the acquisition of proprietary intellectual capital from universities and laboratory research centers. Strategic alliance agreements are generally cancelable by either party with thirty days advance written notice.
About VisiJet, Inc.
VisiJet is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. The EpiLift system is manufactured in Germany by Gebauer Medizintechnik GmbH. For more information about VisiJet, please visit the following website: http://www.advancedrefractive.com.
About UTEK® Corporation
UTEK® is a leading, market-driven technology transfer company that enables companies to rapidly acquire innovative technologies from universities and research laboratories. UTEK facilitates the identification and acquisition of external technologies for clients internationally in exchange for their equity securities, while allowing research institutions to receive 100% of the royalties. This unique process is called U2B®. UTEK transfers proprietary technologies with potential commercial applications to companies seeking product differentiation resulting in a strategic marketplace advantage. UTEK has operations in the United States, United Kingdom and Israel. For more information about UTEK, please visit its website at http://www.utekcorp.com.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as UTEK or VisiJet "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe UTEK`s or VisiJet`s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of UTEK or VisiJet, as appropriate, and the valuation of UTEK`s investment portfolio, which could cause actual results to differ materially from those currently anticipated. Although UTEK and VisiJet believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and both UTEK and VisiJet do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
UTEK`s operating results could fluctuate significantly due to a number of factors. These factors include the small number of transactions that are completed each quarter, the value of individual transactions, the timing of the recognition and the magnitude of unrealized gains and losses, UTEK`s dependence on the performance of companies in its portfolio, the possibility that advances in technology could render the technologies it has transferred obsolete, the loss of technology licenses by companies in its portfolio, the degree to which it encounters competition in its markets, the volatility of the stock market and the volatility of the valuations of the companies it has invested in as it relates to its realized and unrealized gains and losses, the concentration of investments in a small number of companies, as well as other general economic conditions. As a result of these and other factors, current results may not be indicative of UTEK`s future performance. For more information on UTEK and for a more complete discussion of the risks pertaining to an investment in UTEK, please refer to UTEK`s filing with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
SAN CLEMENTE, Calif. & PLANT CITY, Fla.--(BUSINESS WIRE)--May 31, 2005--VisiJet, Inc. (OTCBB:VJET - News) a medical device company, and UTEK Corporation (AMEX:UTK - News; LSE-AIM:UTKA) an innovative technology transfer company, announced today the signing of a strategic alliance agreement.
ADVERTISEMENT
Randy Bailey, President and Chief Executive Officer of VisiJet, Inc., said, "We are enthusiastic about this strategic alliance with UTEK Corporation which will enable us to identify ophthalmic technologies for acquisition."
"UTEK looks forward to working with VisiJet, Inc. to identify and potentially transfer proprietary technologies that will be synergistic with their core business," said Clifford M. Gross, Ph.D., Chairman and Chief Executive Officer of UTEK.
Through its strategic alliance agreements, UTEK assists companies in enhancing their new product pipeline with the acquisition of proprietary intellectual capital from universities and laboratory research centers. Strategic alliance agreements are generally cancelable by either party with thirty days advance written notice.
About VisiJet, Inc.
VisiJet is a medical device company based in Irvine, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. The EpiLift system is manufactured in Germany by Gebauer Medizintechnik GmbH. For more information about VisiJet, please visit the following website: http://www.advancedrefractive.com.
About UTEK® Corporation
UTEK® is a leading, market-driven technology transfer company that enables companies to rapidly acquire innovative technologies from universities and research laboratories. UTEK facilitates the identification and acquisition of external technologies for clients internationally in exchange for their equity securities, while allowing research institutions to receive 100% of the royalties. This unique process is called U2B®. UTEK transfers proprietary technologies with potential commercial applications to companies seeking product differentiation resulting in a strategic marketplace advantage. UTEK has operations in the United States, United Kingdom and Israel. For more information about UTEK, please visit its website at http://www.utekcorp.com.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as UTEK or VisiJet "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe UTEK`s or VisiJet`s future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of UTEK or VisiJet, as appropriate, and the valuation of UTEK`s investment portfolio, which could cause actual results to differ materially from those currently anticipated. Although UTEK and VisiJet believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and both UTEK and VisiJet do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
UTEK`s operating results could fluctuate significantly due to a number of factors. These factors include the small number of transactions that are completed each quarter, the value of individual transactions, the timing of the recognition and the magnitude of unrealized gains and losses, UTEK`s dependence on the performance of companies in its portfolio, the possibility that advances in technology could render the technologies it has transferred obsolete, the loss of technology licenses by companies in its portfolio, the degree to which it encounters competition in its markets, the volatility of the stock market and the volatility of the valuations of the companies it has invested in as it relates to its realized and unrealized gains and losses, the concentration of investments in a small number of companies, as well as other general economic conditions. As a result of these and other factors, current results may not be indicative of UTEK`s future performance. For more information on UTEK and for a more complete discussion of the risks pertaining to an investment in UTEK, please refer to UTEK`s filing with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Eine Empfehlung vom letzen Jahr, hat nicht ganz geklappt mit dem Kurs.
In der aktuellen Ausgabe des Börsenbriefs International Stock Picker empfehlen die Aktien-Experten VisiJet Inc. (WKN: 165219) zum Kauf. Das 12-Monatskursziel liegt bei 2,00 US-Dollar. Derzeit notiert die Aktie bei 0,85 US-Dollar.
Das kalifornische Medizintechnikunternehmen VisiJet Inc. entwickelt innovative Produkte zur Behandlung von Augenkrankheiten mit Fokus auf Linseneintrübungen (Grauer Star) sowie Fehlsichtigkeiten.
Die Hauptprodukte HydroKeratome® und PulsaTome® basieren auf einer eigen entwickelten Wasserstrahltechnologie: Der Mikro-Wasserstrahl ist noch dünner als der Durchmesser eines Haares und schneidet mithilfe von Hochdruck das Augengewebe. Diese Behandlungsmethode bietet einige Vorteile: Geringere Schmerzen, Verbesserung der Sehkraft tritt schneller ein und Narbenbildungen sind seltener.
Anfang Mai 2004 machte VisiJet durch einen cleveren Schachzug auf sich aufmerksam; Man übernahm die weltweiten Vertriebs- und Marketingrechte für die LASIK/Epi-LASIK Produkte der deutschen Gebauer Medizintechnik GmbH. So kann VisiJet schon im zweiten Quartal 2004 erste Umsätze erzielen.
Vor der jüngsten Akquisition sicherte sich VisiJet eine Finanzierung über insgesamt 9,5 Mio. USD. Zwei institutionelle Investoren erhöhten ihre Finanzierungszusagen von 4,5 Mio. USD aus dem letzten Jahr um weitere 5 Mio. USD. Diese Aktien werden zu einem Kurs von 2 USD ausgegeben.
Aktuell beträgt der Börsenwert von VisiJet knapp 23 Mio. USD. Blickt man auf den großen Konkurrenten VISX Inc., sieht man was möglich ist: VISX ist an der Börse bei einem Kurs-Umsatz-Verhältnis von 8 mit rund 1,14 Mrd. USD bewertet. Bei VisiJet ist in 2005 ein Umsatz von mehr als 25 Mio. USD möglich. Verglichen mit VISX ergäbe sich bei VisiJet ein Kurspotential von 900 Prozent. Aufgrund der revolutionären Technologie und des bisherigen sehr positiven Feedbacks von über 150 Chirurgen sind die Chancen hoch, dass VisiJet den Wettbewerbern signifikante Marktanteile abnehmen kann.
In der aktuellen Ausgabe des Börsenbriefs International Stock Picker empfehlen die Aktien-Experten VisiJet Inc. (WKN: 165219) zum Kauf. Das 12-Monatskursziel liegt bei 2,00 US-Dollar. Derzeit notiert die Aktie bei 0,85 US-Dollar.
Das kalifornische Medizintechnikunternehmen VisiJet Inc. entwickelt innovative Produkte zur Behandlung von Augenkrankheiten mit Fokus auf Linseneintrübungen (Grauer Star) sowie Fehlsichtigkeiten.
Die Hauptprodukte HydroKeratome® und PulsaTome® basieren auf einer eigen entwickelten Wasserstrahltechnologie: Der Mikro-Wasserstrahl ist noch dünner als der Durchmesser eines Haares und schneidet mithilfe von Hochdruck das Augengewebe. Diese Behandlungsmethode bietet einige Vorteile: Geringere Schmerzen, Verbesserung der Sehkraft tritt schneller ein und Narbenbildungen sind seltener.
Anfang Mai 2004 machte VisiJet durch einen cleveren Schachzug auf sich aufmerksam; Man übernahm die weltweiten Vertriebs- und Marketingrechte für die LASIK/Epi-LASIK Produkte der deutschen Gebauer Medizintechnik GmbH. So kann VisiJet schon im zweiten Quartal 2004 erste Umsätze erzielen.
Vor der jüngsten Akquisition sicherte sich VisiJet eine Finanzierung über insgesamt 9,5 Mio. USD. Zwei institutionelle Investoren erhöhten ihre Finanzierungszusagen von 4,5 Mio. USD aus dem letzten Jahr um weitere 5 Mio. USD. Diese Aktien werden zu einem Kurs von 2 USD ausgegeben.
Aktuell beträgt der Börsenwert von VisiJet knapp 23 Mio. USD. Blickt man auf den großen Konkurrenten VISX Inc., sieht man was möglich ist: VISX ist an der Börse bei einem Kurs-Umsatz-Verhältnis von 8 mit rund 1,14 Mrd. USD bewertet. Bei VisiJet ist in 2005 ein Umsatz von mehr als 25 Mio. USD möglich. Verglichen mit VISX ergäbe sich bei VisiJet ein Kurspotential von 900 Prozent. Aufgrund der revolutionären Technologie und des bisherigen sehr positiven Feedbacks von über 150 Chirurgen sind die Chancen hoch, dass VisiJet den Wettbewerbern signifikante Marktanteile abnehmen kann.
Hört sich eigentlich vieles interessant an...!Nur,woran liegt dann der Kursverfall??Im tiefst bei 0,032$-jetzt bei 0,007$.Frdl.grüße...D....
Sorry-0,07$,!
Keine Ahnung beobachte sie auch erst seit Threaderöffnung.
Grüße
und Glück
Grüße
und Glück
Sieh Dir an....Handel...232000-stück....außerdem gehen bid und ask schön auseinander!=,055$-zu-0,06 bis 0,13....Das kann heut locker bei 0,08$ schliessen...?!Grüsse...D....
Hätte den Thread es geht wieder runter nennen sollen!
Aber höchstwahrscheinlich wieder Erholung zum Handelsende.
Grüße
Aber höchstwahrscheinlich wieder Erholung zum Handelsende.
Grüße
Hier mal Level 2
Market Depth For Visijet Inc Delayed (10:30 AM EDT)
Level II Quotebook
Time MMID Size Bid
07:30 SCHB 50 0.06
07:30 HDSN 50 0.06
09:17 ETRD 50 0.055 ↓
07:30 HILL 50 0.05
07:30 PERT 50 0.05
07:30 SBSH 50 0.05
07:30 MAXM 50 0.05
07:30 VERT 50 0.05
09:42 NITE 50 0.05 ↓
10:27 TDCM 50 0.05
09:30 GNET 50 0.031 ↑
07:30 FRAN 50 0.03
07:30 SACM 50 0.03
07:56 BEST 50 0.03 ↓
07:30 DOMS 50 0.02
07:30 FLCR 50 0.02 ↓
07:30 JGIO 50 0.010
07:30 VFIN 50 0.010
07:30 VNDM 50 0.001
07:30 AVTG 0 0.000
07:30 TRAC 0 0.000
Ask Size MMID Time
0.065 50 NITE 09:42
0.069 50 SCHB 07:30
↓ 0.07 50 TDCM 10:27
0.075 50 HDSN 07:30
0.08 50 DOMS 07:30
0.08 50 PERT 07:30
0.085 50 ETRD 09:17
0.14 50 HILL 07:30
0.15 50 SBSH 07:30
0.20 50 FRAN 07:30
0.25 50 JGIO 07:30
0.25 50 VERT 07:30
0.26 50 VFIN 07:30
0.30 50 SACM 07:30
0.30 50 MAXM 07:30
0.30 50 FLCR 07:30
↓ 0.30 50 BEST 07:56
2.00 5 VNDM 07:30
25.00 2 AVTG 07:30
Market Depth For Visijet Inc Delayed (10:30 AM EDT)
Level II Quotebook
Time MMID Size Bid
07:30 SCHB 50 0.06
07:30 HDSN 50 0.06
09:17 ETRD 50 0.055 ↓
07:30 HILL 50 0.05
07:30 PERT 50 0.05
07:30 SBSH 50 0.05
07:30 MAXM 50 0.05
07:30 VERT 50 0.05
09:42 NITE 50 0.05 ↓
10:27 TDCM 50 0.05
09:30 GNET 50 0.031 ↑
07:30 FRAN 50 0.03
07:30 SACM 50 0.03
07:56 BEST 50 0.03 ↓
07:30 DOMS 50 0.02
07:30 FLCR 50 0.02 ↓
07:30 JGIO 50 0.010
07:30 VFIN 50 0.010
07:30 VNDM 50 0.001
07:30 AVTG 0 0.000
07:30 TRAC 0 0.000
Ask Size MMID Time
0.065 50 NITE 09:42
0.069 50 SCHB 07:30
↓ 0.07 50 TDCM 10:27
0.075 50 HDSN 07:30
0.08 50 DOMS 07:30
0.08 50 PERT 07:30
0.085 50 ETRD 09:17
0.14 50 HILL 07:30
0.15 50 SBSH 07:30
0.20 50 FRAN 07:30
0.25 50 JGIO 07:30
0.25 50 VERT 07:30
0.26 50 VFIN 07:30
0.30 50 SACM 07:30
0.30 50 MAXM 07:30
0.30 50 FLCR 07:30
↓ 0.30 50 BEST 07:56
2.00 5 VNDM 07:30
25.00 2 AVTG 07:30
Tach!
Langweilig
12:54 ETRD 50 0.053 ↑
13:08 NITE 50 0.052
09:30 GNET 50 0.05 ↑
12:59 SCHB 50 0.05
07:30 TDCM 50 0.045
12:58 PERT 50 0.045 ↑
07:30 HDSN 50 0.04
07:30 HILL 50 0.035
07:30 VERT 50 0.031
07:30 FRAN 50 0.03
07:30 SACM 50 0.03
07:30 SBSH 50 0.03
07:30 DOMS 50 0.02
07:30 MAXM 50 0.02
07:30 FLCR 50 0.02
07:30 JGIO 50 0.01
07:30 VFIN 50 0.01
07:56 BEST 50 0.01 ↓
07:30 VNDM 50 0.001
07:30 INTL 50 0.001
07:30 AVTG 0 0.00
07:30 TRAC 0 0.00
Ask Size MMID Time
↓ 0.055 50 SCHB 12:59
↓ 0.056 50 NITE 13:08
0.07 50 TDCM 07:30
↓ 0.07 50 ETRD 12:54
0.08 50 DOMS 07:30
0.08 50 HDSN 07:30
0.08 50 PERT 12:58
0.12 50 HILL 07:30
0.15 50 SBSH 07:30
0.15 50 VERT 07:30
0.20 50 FRAN 07:30
0.20 50 MAXM 07:30
0.25 50 JGIO 07:30
0.26 50 VFIN 07:30
0.30 50 SACM 07:30
0.30 50 FLCR 07:30
↓ 0.30 50 BEST 07:56
0.55 25 INTL 07:30
2.00 5 VNDM 07:30
25.00 2 AVTG 07:30
Grüße
Langweilig
12:54 ETRD 50 0.053 ↑
13:08 NITE 50 0.052
09:30 GNET 50 0.05 ↑
12:59 SCHB 50 0.05
07:30 TDCM 50 0.045
12:58 PERT 50 0.045 ↑
07:30 HDSN 50 0.04
07:30 HILL 50 0.035
07:30 VERT 50 0.031
07:30 FRAN 50 0.03
07:30 SACM 50 0.03
07:30 SBSH 50 0.03
07:30 DOMS 50 0.02
07:30 MAXM 50 0.02
07:30 FLCR 50 0.02
07:30 JGIO 50 0.01
07:30 VFIN 50 0.01
07:56 BEST 50 0.01 ↓
07:30 VNDM 50 0.001
07:30 INTL 50 0.001
07:30 AVTG 0 0.00
07:30 TRAC 0 0.00
Ask Size MMID Time
↓ 0.055 50 SCHB 12:59
↓ 0.056 50 NITE 13:08
0.07 50 TDCM 07:30
↓ 0.07 50 ETRD 12:54
0.08 50 DOMS 07:30
0.08 50 HDSN 07:30
0.08 50 PERT 12:58
0.12 50 HILL 07:30
0.15 50 SBSH 07:30
0.15 50 VERT 07:30
0.20 50 FRAN 07:30
0.20 50 MAXM 07:30
0.25 50 JGIO 07:30
0.26 50 VFIN 07:30
0.30 50 SACM 07:30
0.30 50 FLCR 07:30
↓ 0.30 50 BEST 07:56
0.55 25 INTL 07:30
2.00 5 VNDM 07:30
25.00 2 AVTG 07:30
Grüße
Was soll passieren???
NASDAQ to Transfer the Over-the-Counter Bulletin Board to the NASD
Summary
The NASDAQ Stock Market will be transferring the OTCBB and the trade reporting of all other Over-the-Counter (OTC) securities to the NASD.
NASDAQ will continue to operate the OTCBB in a facilities arrangement only.
Accessibility to the OTCBB through all of NASDAQ’s connectivity channels will remain the same.
Contact information
Background
The Nasdaq Stock Market, Inc.® announced today that it plans to enter into an agreement in principle to transfer the Over-the-Counter Bulletin Board® (OTCBB) business and the trade reporting of all other Over-the-Counter (OTC) securities to NASD. The transfer is subject to approval from the Securities and Exchange Commission (SEC), the signing of a definitive agreement, and other necessary approvals. This development is designed to facilitate corporate structure changes related to NASDAQ achieving exchange status.
NASDAQ and NASD have structured this transfer of the businesses to be seamless to the customers of the OTCBB and OTC trade reporting businesses. NASDAQ® will continue to provide the technology and connectivity used to carry out the day-to-day functions of the OTCBB and OTC trade reporting while the OTCBB business will be owned, managed and continued to be regulated by the NASD.
The OTCBB will continue to be accessed through the existing channels: the NASDAQ Workstation II® and application programming interface (API) (both available until October 31, 2005), the computer-to-computer interface (CTCI), and through NASDAQ’s new offerings in 2005, QIX, NASDAQ’s proprietary connectivity protocol, and the new NASDAQ Workstation. OTCBB market data will also continue to be offered through the Bulletin Board Dissemination ServiceSM (BBDSSM) and the NASDAQ Trade Data Dissemination ServiceSM (TDDSSM).
NASDAQ will provide more information on the OTCBB transfer as the details are finalized. We look forward to an efficient transition.
Contact Information
Questions may be addressed to:
Karen Peterson at 212.401.8795;
Stacie Swanstrom at 301.978.8101;
Colleen Lampe at 301.978.8258;
Email the OTC Bulletin Board; or
Karen Sancilio (NASD) at 866.749.7096.
--------------------------------------------------------------------------------
The OTC Bulletin Board (OTCBB) is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter (OTC) equity securities. An OTC equity security generally is any equity that is not listed or traded on NASDAQ or a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, ADRs, and Direct Participation Programs (DPPs).
NASDAQ is the largest U.S. electronic stock market. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ Trader website at www.NASDAQtrader.com.
NASDAQ to Transfer the Over-the-Counter Bulletin Board to the NASD
Summary
The NASDAQ Stock Market will be transferring the OTCBB and the trade reporting of all other Over-the-Counter (OTC) securities to the NASD.
NASDAQ will continue to operate the OTCBB in a facilities arrangement only.
Accessibility to the OTCBB through all of NASDAQ’s connectivity channels will remain the same.
Contact information
Background
The Nasdaq Stock Market, Inc.® announced today that it plans to enter into an agreement in principle to transfer the Over-the-Counter Bulletin Board® (OTCBB) business and the trade reporting of all other Over-the-Counter (OTC) securities to NASD. The transfer is subject to approval from the Securities and Exchange Commission (SEC), the signing of a definitive agreement, and other necessary approvals. This development is designed to facilitate corporate structure changes related to NASDAQ achieving exchange status.
NASDAQ and NASD have structured this transfer of the businesses to be seamless to the customers of the OTCBB and OTC trade reporting businesses. NASDAQ® will continue to provide the technology and connectivity used to carry out the day-to-day functions of the OTCBB and OTC trade reporting while the OTCBB business will be owned, managed and continued to be regulated by the NASD.
The OTCBB will continue to be accessed through the existing channels: the NASDAQ Workstation II® and application programming interface (API) (both available until October 31, 2005), the computer-to-computer interface (CTCI), and through NASDAQ’s new offerings in 2005, QIX, NASDAQ’s proprietary connectivity protocol, and the new NASDAQ Workstation. OTCBB market data will also continue to be offered through the Bulletin Board Dissemination ServiceSM (BBDSSM) and the NASDAQ Trade Data Dissemination ServiceSM (TDDSSM).
NASDAQ will provide more information on the OTCBB transfer as the details are finalized. We look forward to an efficient transition.
Contact Information
Questions may be addressed to:
Karen Peterson at 212.401.8795;
Stacie Swanstrom at 301.978.8101;
Colleen Lampe at 301.978.8258;
Email the OTC Bulletin Board; or
Karen Sancilio (NASD) at 866.749.7096.
--------------------------------------------------------------------------------
The OTC Bulletin Board (OTCBB) is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter (OTC) equity securities. An OTC equity security generally is any equity that is not listed or traded on NASDAQ or a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, ADRs, and Direct Participation Programs (DPPs).
NASDAQ is the largest U.S. electronic stock market. With approximately 3,200 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ Trader website at www.NASDAQtrader.com.
evtl. interessiert es einen
Level II Quotebook
Time MMID Size Bid
11:01 HDSN 50 0.057 ↑
09:28 ETRD 50 0.055 ↑
09:53 SCHB 50 0.051
11:31 NITE 50 0.051
07:43 PERT 50 0.05 ↑
09:30 GNET 50 0.05 ↑
07:30 TDCM 50 0.045
07:30 HILL 50 0.035
07:30 VERT 50 0.031
07:30 FRAN 50 0.03
07:30 SACM 50 0.03
07:30 SBSH 50 0.03
07:30 DOMS 50 0.02
07:30 MAXM 50 0.02
07:30 FLCR 50 0.02
07:30 JGIO 50 0.01
07:30 VFIN 50 0.01
07:56 BEST 50 0.01 ↓
07:30 VNDM 50 0.001
07:30 INTL 50 0.001
07:30 AVTG 0 0.00
07:30 TRAC 0 0.00
Ask Size MMID Time
↑ 0.065 50 SCHB 09:53
↑ 0.065 50 NITE 11:31
0.07 50 TDCM 07:30
0.07 50 ETRD 09:28
0.08 50 DOMS 07:30
0.08 50 PERT 07:43
↑ 0.107 50 HDSN 11:01
0.12 50 HILL 07:30
0.15 50 SBSH 07:30
0.15 50 VERT 07:30
0.20 50 FRAN 07:30
0.20 50 MAXM 07:30
0.25 50 JGIO 07:30
0.26 50 VFIN 07:30
0.30 50 SACM 07:30
0.30 50 FLCR 07:30
↓ 0.30 50 BEST 07:56
0.55 25 INTL 07:30
2.00 5 VNDM 07:30
25.00 2 AVTG 07:30
Gruß
Level II Quotebook
Time MMID Size Bid
11:01 HDSN 50 0.057 ↑
09:28 ETRD 50 0.055 ↑
09:53 SCHB 50 0.051
11:31 NITE 50 0.051
07:43 PERT 50 0.05 ↑
09:30 GNET 50 0.05 ↑
07:30 TDCM 50 0.045
07:30 HILL 50 0.035
07:30 VERT 50 0.031
07:30 FRAN 50 0.03
07:30 SACM 50 0.03
07:30 SBSH 50 0.03
07:30 DOMS 50 0.02
07:30 MAXM 50 0.02
07:30 FLCR 50 0.02
07:30 JGIO 50 0.01
07:30 VFIN 50 0.01
07:56 BEST 50 0.01 ↓
07:30 VNDM 50 0.001
07:30 INTL 50 0.001
07:30 AVTG 0 0.00
07:30 TRAC 0 0.00
Ask Size MMID Time
↑ 0.065 50 SCHB 09:53
↑ 0.065 50 NITE 11:31
0.07 50 TDCM 07:30
0.07 50 ETRD 09:28
0.08 50 DOMS 07:30
0.08 50 PERT 07:43
↑ 0.107 50 HDSN 11:01
0.12 50 HILL 07:30
0.15 50 SBSH 07:30
0.15 50 VERT 07:30
0.20 50 FRAN 07:30
0.20 50 MAXM 07:30
0.25 50 JGIO 07:30
0.26 50 VFIN 07:30
0.30 50 SACM 07:30
0.30 50 FLCR 07:30
↓ 0.30 50 BEST 07:56
0.55 25 INTL 07:30
2.00 5 VNDM 07:30
25.00 2 AVTG 07:30
Gruß
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
117 | ||
74 | ||
54 | ||
49 | ||
37 | ||
36 | ||
35 | ||
34 | ||
33 | ||
33 |
Wertpapier | Beiträge | |
---|---|---|
32 | ||
31 | ||
29 | ||
29 | ||
29 | ||
28 | ||
28 | ||
26 | ||
24 | ||
23 |